Term
click below
click below
Term
Normal Size Small Size show me how
PTA Cardio Pharm
Pharmacology for Cardio Disease Management
Term | Definition |
---|---|
Alpha Adrenergic Antagonist Agents | Reduce perohperal vascular tone by blocking alpha-1-adrenergic receptors; causes dilation and decrease in BP |
ACE Inhibitor Agents | Suppresses enzyme that converts angiotensin 1 into angiotensin 2; decreasing blood pressure and after load |
Anticoagulant Agents | Inhibit platelet aggregation and thrombus formation |
Anti-hyperlipidemia Agents | AKA Statins; lipid modifying agents; inhibit anzyme aciton in cholesterol synthesis, break down LDL, decrease triglycerides, and increase HDL |
Anti-thrombotic Agents | inhibit platelet aggregation and clot formation |
Beta Blocker Agents | Block B-Adrenergic receptors; decrease myocardial oxygen demand by decreasing heart rate and contractility |
Calcium Channel Blocker Agents | Decrease calcium entry int o calcium smooth mm cells resulting in diminished myocardial contraction, vasodilation, and oxygen demand |
Diuretic Agents | Increase secretion of sodium and urine => reduction in plasma volume and BP; thiazide, loop and potassium sparing |
Nitrate Agents | Decrease ischemia through smooth mm relaxation and dilation of peripheral vessels |
Positive Inotropic Agents | Increase force and velocity of myocardial contraction; slow the heart rate; decrease conduction velocity through AV node and decrease degree of activation of SNS |
Thrombolytic Agents | Facilitate clot dissolution through conversion of plasminogen to plasmin; plasmin breaks down clots and opens blood vessels |